Lerodalcibep is an adnectin-based, small protein-binding, third generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.
The NHS Long Term Plan committed to rolling out the Enhanced health in care homes (EHCH) model across England by 2024. This was achieved ahead of schedule in 2020. This model moves away from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback